A team of researchers from City of Hope and The University of Texas M.D. Anderson Cancer Center has reported safety and efficacy results from a Phase 1 trial that featured a personalized vaccine to treat lymphoplasmacytic lymphoma, a rare and slow-growing type of blood cancer, according to a study published recently in Nature Communications.
Vaccine experts report positive results on Phase 1 trial of personalized vaccine for lymphoplasmacytic lymphoma
